Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23352320 | 0.90 | COMT (0.44) | MAPK14HTR1ADRD2BRD4 | |
| SCHEMBL10674817 | 0.82 | MAPK14 (0.52) | MAPK14MEN1ALDH1A1HPGDHTT | |
| SCHEMBL23046958 | 0.80 | COMT (0.45) | MAPK14HTR1ADRD2ABCB1BRD4 | |
| SCHEMBL23046938 | 0.80 | MAPK14 (0.44) | MAPK14MEN1ALDH1A1HPGDHTT | |
| SCHEMBL13555540 | 0.77 | MAPK14 (0.46) | MAPK14MEN1ALDH1A1HPGDHTT | |
| Hydrochloric Acid SCHEMBL13386403 | 0.76 | MAPK14 (0.45) | MAPK14MEN1ALDH1A1HPGDHTT | |
| SCHEMBL28506693 | 0.72 | COMT (0.56) | MAPK14HTR1ADRD2BRD4 | |
| SCHEMBL9652539 | 0.71 | MAPK14 (0.49) | MAPK14MEN1ALDH1A1HPGDHTT | |
| SCHEMBL10665233 | 0.71 | MAPK14 (0.49) | MAPK14MEN1ALDH1A1HPGDHTT | |
| SCHEMBL20540841 | 0.70 | COMT (0.41) | MAPK14GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380471-B1 | TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20180305354-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | disclosed |
| WO-2017091818-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305354-A1 | COMT Inhibiting Methods and Compositions | COMT, MAOB, MAOA | MAPK14 3441/4885HTR1A 21/4885DRD2 219/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | MAPK14 3582/4885HTR1A 83/4885DRD2 263/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | MAPK14 3441/4885HTR1A 21/4885DRD2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.